David L. Baker
Princess Margaret Hospital for Children
60 Papers
466 Citations
David L. Baker is an academic researcher from Princess Margaret Hospital for Children. The author has contributed to research in topics: Medicine & Acute lymphocytic leukemia. The author has an hindex of 23, co-authored 57 publications. Previous affiliations of David L. Baker include University of Pennsylvania & Children's Hospital of Philadelphia.
Chat about Author
Papers
Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma
David L. Baker,Mary Lou Schmidt,Susan L. Cohn,John M. Maris,Wendy B. London,Allen Buxton,Daniel O. Stram,Robert P. Castleberry,Hiroyuki Shimada,Anthony D. Sandler,Robert C. Shamberger,A. Thomas Look,C. Patrick Reynolds,Robert C. Seeger,Katherine K. Matthay +14 more
TL;DR: A very high rate of survival among patients with intermediate-risk neuroblastoma was achieved with a biologically based treatment assignment involving a substantially reduced duration of chemotherapy and reduced doses of chemotherapeutic agents as compared with the regimens used in earlier trials.
Medulloblastoma Down Under 2013: A report from the third annual meeting of the International Medulloblastoma Working Group.
Nicholas G. Gottardo,Nicholas G. Gottardo,Jordan R. Hansford,Jacqueline P. McGlade,Frank Alvaro,David M. Ashley,Simon Bailey,David L. Baker,Franck Bourdeaut,Yoon Jae Cho,Moira A Clay,Steven C. Clifford,Richard J. Cohn,Catherine H. Cole,Catherine H. Cole,Peter B. Dallas,Peter Downie,Peter Downie,François Doz,François Doz,David W. Ellison,Raelene Endersby,Paul G. Fisher,Tim Hassall,John A. Heath,Hilary Hii,David T.W. Jones,Reimar Junckerstorff,Reimar Junckerstorff,Stewart J. Kellie,Marcel Kool,Rishi S. Kotecha,Rishi S. Kotecha,Peter Lichter,Stephen J. Laughton,Sharon X. Lee,Geoff McCowage,Paul A. Northcott,James M. Olson,Roger J. Packer,Stefan M. Pfister,Torsten Pietsch,Barry Pizer,Scott L. Pomeroy,Marc Remke,Giles W. Robinson,Stefan Rutkowski,Tobias Schoep,Anang A. Shelat,Clinton F. Stewart,Michael J. Sullivan,Michael D. Taylor,Brandon J. Wainwright,Thomas Walwyn,William A. Weiss,Daniel Williamson,Amar Gajjar +56 more
TL;DR: A consensus was reached that a novel classification scheme for medulloblastoma based on the four molecular subgroups, as well as histopathologic features, should be presented for consideration in the upcoming fifth edition of the World Health Organization’s classification of tumours of the central nervous system.
The effectiveness of a peer support camp for siblings of children with cancer
TL;DR: This first study to report on the mental health of Australian siblings of children with cancer and examines the effects of a therapeutic peer support camp—Camp Onwards, as an intervention.
98
Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse.
Tina Carter,Paul M. Watt,Rolee Kumar,Paul Burton,Gregory H. Reaman,Harland N. Sather,David L. Baker,Ursula R. Kees +7 more
- 15 Jan 2001
TL;DR: The study revealed, strikingly, that the risk ratio for relapse for hemizygous deletion compared with no deletion was 6.558 and that homozygous deletion of p16 in pediatric ALL patients is an independent prognostic indicator of outcome from therapy.
97
Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG)
Ursula R. Kees,Nyla A. Heerema,Riten Kumar,Paul M. Watt,David L. Baker,Mei La,Fatih M. Uckun,H N Sather +7 more
TL;DR: Direct cytogenetic analysis revealed that only 2/16 specimens that showed HOX11 expression exhibited abnor-malities at 10q24, and implicate mechanisms other than gross chromosomal translocations for the deregulation of HOX 11.
85